Intravitreal injections of anti-vascular endothelial growth factor (VEGF), such as intravitreal injection of bevacizumab (IVB), a widely used treatment of ROP, are associated with systemic risks since they can enter the systemic circulation and lead to systemic VEGF suppression for up to 8 weeks after injection [23,24,25,26]. Here, VEGFA is linked to retinopathy of prematurity.